Sulopenem Etzadroxil And Probenecid has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ketorolac Tromethamine, Ketoprofen, Indomethacin. Patients taking Sulopenem Etzadroxil And Probenecid should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Contraindicated
- 1
- Major
- 1
- Moderate
- 5
- Minor
- 1
Contraindicated (1)
- Sulopenem Etzadroxil And Probenecid + Ketorolac Tromethamine— Probenecid component inhibits OAT1/3, increasing ketorolac tromethamine plasma concentrations and risk of adverse reacti…
Major (1)
- Sulopenem Etzadroxil And Probenecid + Ketoprofen— Probenecid inhibits OAT1/3, increasing ketoprofen plasma concentrations. Concomitant use is not recommended.
Moderate (5)
- Sulopenem Etzadroxil And Probenecid + Indomethacin— Probenecid inhibits OAT1/3, increasing indomethacin plasma concentrations and risk of adverse reactions. May require dos…
- Sulopenem Etzadroxil And Probenecid + Lorazepam— Probenecid inhibits OAT1/3, increasing lorazepam plasma concentrations. Follow recommended lorazepam dosage modification…
- Sulopenem Etzadroxil And Probenecid + Methotrexate— Probenecid inhibits OAT1/3, increasing methotrexate plasma concentrations. Monitor frequently for adverse reactions if c…
- Sulopenem Etzadroxil And Probenecid + Naproxen— Probenecid inhibits OAT1/3, increasing naproxen plasma concentrations and risk of adverse reactions. May require dosage …
- Sulopenem Etzadroxil And Probenecid + Rifampin— Probenecid inhibits OAT1/3, increasing rifampin plasma concentrations. Monitor more frequently for adverse reactions.
Minor (1)
- Sulopenem Etzadroxil And Probenecid + Valproic Acid— No clinically significant reduction in valproic acid plasma concentrations observed with concomitant use. No dosage adju…